earnings
confidence high
sentiment positive
materiality 0.75
Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M
Innoviva, Inc.
2026-Q1 EPS reported
$2.22
revenue$97,994,000
- Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
- Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.
- Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.
- Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.
- NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026.
item 2.02item 9.01